Fluxion Biosciences Announces Product Launch of IsoFlux System for Circulating Tumor Cell Analysis

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Fluxion Biosciences, Inc. announced today that it has launched its IsoFlux System for circulating tumor cell (CTC) analysis at the 3rd annual World CTC Summit in Boston. The system is now commercially available and will begin shipping to customers. The IsoFlux System is a benchtop instrument that utilizes a proprietary microfluidic technology to isolate CTCs and other rare cell types from blood samples. CTCs disseminate from primary tumors and circulate throughout the peripheral blood in concentrations around 1 CTC in a billion blood cells. This falls below the sensitivity limits of convention cell sorting technologies. The IsoFlux System was designed to isolate rare CTCs with high capture efficiency and pass them on to downstream analyses.